GSK Stock Recent News

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.

PHILADELPHIA--(BUSINESS WIRE)-- #Adult--GSK announces positive topline data on co-administration of AREXVY and SHINGRIX.

Brooke Shields convenes other celebrities, influencers and patient advocates over 50 to discuss the power of aging and how to protect their health Shields directs a short film, encouraging adults 50 years of age and older to talk to their doctor or pharmacist about their risk for shingles — a disease that affects about 1 million people annually in the US — and about vaccination The partnership is part of GSK's national THRIVE@50+ campaign PHILADELPHIA , Sept. 16, 2024 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) is partnering with Brooke Shields, as part of its THRIVE@50+ campaign, to encourage people 50 and older to embrace and protect the power they've found in aging by asking their doctor or pharmacist about their risk for shingles and about vaccination.

Huntsville, Alabama--(Newsfile Corp. - September 16, 2024) - Kalm Therapeutics (Kalm Tx) is pleased to announce the appointment of Dr. Tomoko Maeda-Chubachi, M.D., Ph.D., as our Chief Medical Officer.

GSK PLC (LSE:GSK, NYSE:GSK) announced that its blood cancer drug Blenrep (belantamab mafodotin), in combination with two current treatments, has received Breakthrough Therapy Designation (BTD) in China. This award, granted by the National Medical Products Administration (NMPA), is aimed at speeding up the development of treatments for serious diseases that show promise in improving patient outcomes over current options.

The phase I/II proof-of-concept study evaluating GSK's herpes simplex virus vaccine candidate, GSK3943104, fails to meet the primary efficacy objective.

Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's proprietary second-generation mRNA backbone GSK confirmed data support advancing program to Phase 3; dosing of first Phase 3 participant is associated with a significant milestone payment for CureVac In July 2024, GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 12, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that GSK has reported positive Phase 2 headline data from the seasonal influenza mRNA vaccine program.

British drugmaker GSK on Thursday announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now progress to late-stage clinical development.

GSK PLC (LSE:GSK, NYSE:GSK) has been reiterated as a 'buy' at broker Berenberg, which sees some of the ‘clouds of doubt' that have plagued the pharma group's summer starting to ease. Zantac litigation in Delaware has been the main drag says the broker, but changes to  US  recommendations for Arexvy have also been a worry.

Shares in GSK PLC (LSE:GSK, NYSE:GSK) fell over 1% after the drug maker said it would abandon further trials for a potential herpes vaccine after disappointing results from its clinical trials so far. The FTSE 100 group said data from the phase II part of a proof-of-concept study of the vaccine candidate showed the drug, known as GSK3943104, showed it "did not meet the study's primary efficacy objective".